Opinion

Tuttle v. Commissioner of Social Security

Court
District Court, N.D. Ohio
Filed
Jun 23, 2025
Cited by
0 cases
Authority
More cited than 36.9%

“Our review of the ALJ's decision is limited to whether the ALJ applied the correct legal standards and whether the findings of the ALJ are supported by substantial evidence.”

How later courts described this case

  • “Our review of the ALJ's decision is limited to whether the ALJ applied the correct legal standards and whether the findings of the ALJ are supported by substantial evidence.”

Written by the judges who cited it.

The opinion

IN THE UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF OHIO

EASTERN DIVISION

CARLA LEE TUTTLE, CASE NO. 1:24-CV-01188

Plaintiff,

JUDGE JOHN R. ADAMS

vs.

MAGISTRATE JUDGE AMANDA M. KNAPP

COMMISSIONER OF SOCIAL SECURITY,

Defendant. REPORT AND RECOMMENDATION

Plaintiff Carla Lee Tuttle (“Plaintiff” or “Ms. Tuttle”) seeks judicial review of the final

decision of Defendant Commissioner of Social Security (“Commissioner”) denying her

application for Disability Insurance Benefits (“DIB”). (ECF Doc. 1.) This Court has jurisdiction

pursuant to 42 U.S.C. § 405(g). This matter has been referred to the undersigned Magistrate

Judge for a Report and Recommendation pursuant to Local Rule 72.2.

For the reasons set forth below, the undersigned recommends that the Court AFFIRM

the Commissioner’s decision.

I. Procedural History

Ms. Tuttle filed her DIB application on January 6, 2022, alleging disability beginning

April 1, 2015. (Tr. 17, 139-45.) She alleged disability due to polyneuropathy, Marfan

Syndrome, sacrococcygeal disorder, axonal sensorimotor polyneuropathy, osteoarthritis multiple

joints, lumbago with sciatica, tenosynovitis, heart condition, anxiety, hearing aids, and ankle

braces. (Tr. 57, 66, 164, 191.) Her application was denied at the initial level (Tr. 76-80) and

upon reconsideration (Tr. 82-86). She then requested a hearing. (Tr. 87-88.)

On August 23, 2023, a telephonic hearing was held before an Administrative Law Judge

(“ALJ”). (Tr. 32-56.) The ALJ issued an unfavorable decision on October 9, 2023, finding Ms.

Tuttle had not been under a disability from April 1, 2015, the alleged onset date, through

September 30, 2020, the date last insured. (Tr. 14-31.) Plaintiff requested review of the decision

by the Appeals Council. (Tr. 135-38.) The Appeals Council denied her request for review on

May 16, 2024, making the ALJ’s decision the final decision of the Commissioner. (Tr. 1-6.)

Plaintiff filed the pending appeal on July 15, 2024 (ECF Doc. 1), and the matter is fully briefed

(ECF Docs. 9, 12, 13).

II. Evidence

A. Personal, Educational, and Vocational Evidence

Ms. Tuttle was born in 1971. (Tr. 25, 139.) She was 48 years old as of her date last

insured. (Tr. 25.) She has a high school education and three years of echo tech training. (Tr. 25,

40, 165.) She last worked in 2015 as an echo tech, performing ultrasounds. (Tr. 38, 40.)

B. Medical Evidence

1. Relevant Treatment History1

i. Records Between the Alleged Onset Date and Date Last Insured

Ms. Tuttle treated with her primary care provider Adam J. Bihl, M.D., at Avita Health

System, throughout the relevant period. When she saw Dr. Bihl on March 7, 2016, for a well

1 Ms. Tuttle alleges disability due to physical and mental impairments (Tr. 57, 66, 164, 191) and her “Statement of

Issues” heading mentions a challenge to the mental RFC (ECF Doc. 9, pp. 1, 9), but she does not develop any

arguments relating to her mental impairments. Accordingly, the medical evidence summarized herein is focused on

her physical impairments, and any arguments relating to her mental impairments is deemed waived. See McPherson

v. Kelsey, 125 F.3d 989, 995-96 (6th Cir. 1997) (“[I]ssues adverted to in a perfunctory manner, unaccompanied by

some effort at developed argumentation, are deemed waived.”) (internal citations omitted) (alterations in original).

visit, one of her diagnoses was polyneuropathy, unspecified. (Tr. 265.) Her physical

examination findings were normal. (Tr. 267.) Her medications included gabapentin and

meloxicam. (Tr. 268.) On September 29, 2016, Ms. Tuttle returned to Dr. Bihl for an office

visit relating to her neuropathy. (Tr. 260.) Examination findings were normal. (Tr. 262.)

On April 17, 2017, Ms. Tuttle presented to Kevin McGarvey, D.P.M., for complaints of

bilateral neuropathy and deformed toes, with a chief complaint of bilateral pain in the second toe.

(Tr. 270.) She reported that walking aggravated her pain. (Id.) She also reported having

Marfan’s disease, taking gabapentin and Mobic for neuropathy, and wearing orthotics daily.

(Id.) She asked whether getting a new set of orthotics would help her neuropathy. (Id.) Her

pulses were 2/4 bilaterally and she had diminished sensations bilaterally with Semmes-Weinstein

monofilament (SWMF) test and a history of nerve pain. (Id.) Dr. McGarvey did not recommend

new orthotics or surgery, noting that Ms. Tuttle’s neuropathy and toe deformities could not be

corrected or changed with orthotics. (Id.)

Ms. Tuttle returned to Dr. Bihl for follow up on neuropathy and primary osteoarthritis

involving multiple joints on May 10, 2017; examination findings were unremarkable. (Tr. 381.)

On June 14, 2017, Lindsey Wolf, CNP, at Avita Ontario Family Medicine treated

Plaintiff for left hip pain. (Tr. 379-80.) Ms. Tuttle reported that she “bent down and felt a

ripping sensation.” (Tr. 379.) She rated her pain as 6/7 at rest but 10/10 when walking. (Id.)

She said her pain radiated down her left leg with a burning sensation. (Id.) She also complained

of back pain on the lower-left side, spasms, and a history of right hip pain. (Id.) She said she

tried muscle relaxers and ice with mild relief. (Id.) On examination, Ms. Tuttle’s reflexes were

decreased on the left side. (Tr. 380.) CNP Wolf noted pain with palpation near her left hip,

lower back, and S1 and S2 vertebrae. (Id.) Her range of motion could not be assessed because

she was unable to rotate her hip or leg. (Id.) CNP Wolf assessed left hip and back pain, likely

related to sciatic nerve impingement. (Id.) She started Ms. Tuttle on prednisone to reduce

inflammation and also started her on a muscle relaxer. (Id.)

On September 29, 2017, Ms. Tuttle returned to Dr. Bihl. (Tr. 376.) She complained of

right elbow pain starting the month prior, after “cutting a lot of wood.” (Id.) She also reported

bruising easily with no known reason and requested neuropathy medication refills. (Id.) She had

tried taking Mobic and was using a brace for her tendonitis. (Id.) Examination findings were

generally unremarkable, except Dr. Bihl noted that her lateral epicondyle was tender and there

was pain with resisted supination and extension at the wrist. (Tr. 377.) Ms. Tuttle’s diagnoses

included: neuropathy; primary osteoarthritis; abnormal bruising; lateral epicondylitis,

unspecified laterality; and sciatic nerve pain on the left. (Id.) Dr. Bihl continued Ms. Tuttle’s

prescriptions for 300 mg gabapentin twice a day for neuropathy and 15 mg meloxicam once a

day for primary osteoarthritis involving multiple joints. (Id.) He advised Ms. Tuttle to use rest,

ice, compression, and elevation (RICE) and a forearm strap for her elbow. (Id.)

On March 29, 2018, Ms. Tuttle saw Dr. Bihl for shortness of breath starting two months

earlier. (Tr. 368.) She also presented for follow up regarding her arthritis, indicating that her

symptoms were well controlled. (Id.) Examination findings were unremarkable. (Tr. 369.) Her

diagnoses included neuropathy, for which she was prescribed 300 mg gabapentin twice a day,

and primary osteoarthritis, for which she was prescribed 15 mg meloxicam once a day. (Id.)

On April 9, 2018, Ms. Tuttle returned to podiatrist Dr. McGarvey, complaining of a

chronic ingrown nail on her left second toe that underwent temporary nail correction and healed

well. (Tr. 271.) She reported having pain to her forefoot with weightbearing. (Id.) She was

able to heel and toe walk with ease and rise from a seated position unassisted. (Id.) Dr.

McGarvey surgically removed the entire nail. (Id.) When she returned to Dr. McGarvey for

follow up on April 23, 2018, she reported no pain to the forefoot with weightbearing and she was

doing well postoperatively. (Tr. 272.)

On August 24, 2018, Ms. Tuttle presented to Kelly Y. Osborne, PA-C, at the Avita

Ontario Emergency Department, complaining of a flare up of low back pain radiating into the

right buttock and right leg. (Tr. 642.) She had been doing a lot around the house, which she

thought might have caused the flare up. (Id.) She was able to ambulate, had no weakness in her

extremities, and had no numbness or tingling in her legs. (Id.) On examination, PA Osborne

noted decreased range of motion, tenderness, and pain in the lower back. (Tr. 645.) Her straight

leg raise test and gait were normal. (Id.) She was treated with medication for symptomatic relief

and referred to Dr. David Fitch for physical medicine and rehabilitation. (Tr. 642, 647-48.)

On October 4, 2018, Ms. Tuttle followed up with David S. Fitch, D.O., at Avita Spine &

Physical Medicine and Rehabilitation regarding a back pain flare that had caused her to seek

emergency treatment in August. (Tr. 636.) She reported that her back pain was aggravated by

sitting, lifting, and standing. (Id.) She also reported numbness and tingling. (Id.) Her

examination showed 2+ reflexes and 5/5 strength in the bilateral lower extremities. (Tr. 636-37.)

Dr. Fitch noted diminished sensation to light touch in the bilateral feet in a stocking pattern

consistent with Ms. Tuttle’s history of neuropathy. (Tr. 637.) Her plantar responses were

“downgoing.” (Id.) Her straight leg raise and Spurling tests were negative. (Id.) Hip and SI

joint provocative tests were mildly positive on the right. (Id.) Ms. Tuttle reported feeling a lot

better since her recent exacerbation; she felt she was back to her baseline. (Id.) Dr. Fitch

recommended a lumbar spine x-ray due to her on-and-off back pain for ten years. (Id.) He also

raised the possibility of physical therapy, but Ms. Tuttle felt she was back to baseline and did not

need physical therapy. (Id.) Dr. Fitch recommended home exercises as tolerated, discussed

over-the-counter medications, including Acetaminophen and NSAIDs, and noted that she was

taking gabapentin for her neuropathy. (Id.) He refilled her prescription for Flexeril. (Id.)

On November 12, 2018, Ms. Tuttle returned to Dr. Bihl for follow up. (Tr. 355.) She

reported that her arthritis symptoms were well controlled, she had no medication side effects, and

she did not need any refills. (Id.) She had stopped taking meloxicam because it was not helping.

(Id.) She continued to report neuropathy-related pain in her feet and reported that she had been

taking extra neuropathy medication at bedtime three to four times a week due to increased

neuropathic pain at night. (Id.) Examination findings were unremarkable. (Tr. 357.) Dr. Bihl

increased Ms. Tuttle’s gabapentin to 300 mg three times a day. (Id.)

Ms. Tuttle returned to Dr. Fitch for follow up on December 26, 2018. (Tr. 622.) She

continued to report some right-sided low back pain, but without radiation down her leg. (Id.)

She continued to have numbness in her feet but said it was not new, noting that she had

numbness in her feet for about four years. (Id.) On examination, her lower extremity strength

was within functional limits and she was able to heel/toe walk. (Id.) Dr. Fitch noted that Ms.

Tuttle’s lumbar spine x-rays from October 4, 2018, showed well-preserved vertebral body

heights and disc spaces, minimal scoliosis convex to the right, SI joint spaces were patent, hip

joint spaces were well preserved, and there were no significant facet joint degenerative changes

appreciated. (Id.; see also Tr. 635, 640.) Dr. Fitch concluded that Ms. Tuttle was mostly

recovered from her recent right SI joint pain exacerbation and there were no signs or symptoms

of lumbosacral radiculopathy. (Tr. 623.) He indicated that her chronic bilateral foot numbness

had an uncertain etiology. (Id.) He refilled Ms. Tuttle’s Flexeril and noted that a prednisone

burst and Acetaminophen had helped her the prior week. (Id.) He also noted that Ms. Tuttle

continued to take gabapentin for her chronic foot paresthesia. (Id.) He recommended home

exercises for her low back and referred her to neurology for a determination of the etiology and

appropriate treatment for her chronic bilateral foot numbness. (Id.)

Ms. Tuttle returned to Dr. Bihl on May 8, 2019. (Tr. 347.) She requested a refill of the

muscle relaxer that Dr. Fitch had prescribed, indicating she was taking it daily at most and that it

worked well with no side effects. (Id.) She reported that her arthritis symptoms were well

controlled. (Id.) She continued to report neuropathy-related pain in her feet. (Id.) Examination

findings were unremarkable. (Tr. 348.) Dr. Bihl prescribed 300 mg gabapentin to be taken once

in the morning, once at mid-day, and twice at bedtime. (Id.) He also prescribed cyclobenzaprine

for muscle spasms, to be taken three times daily as needed. (Id.)

Ms. Tuttle returned to Dr. Bihl on November 5, 2019. (Tr. 342.) She reported a flare up

in her joints and noted that her sister had been diagnosed with rheumatoid arthritis. (Id.) She

continued to report neuropathic pain in her feet. (Id.) She also reported that sacroiliac joint pain

caused her back to go out and caused her hip pain. (Id.) Taking muscle relaxers as needed for

her sacroiliac joint pain helped. (Id.) She also reported knee pain, for which she took Tylenol as

needed. (Id.) Examination findings were unremarkable. (Tr. 343.) Dr. Bihl continued Ms.

Tuttle’s prescriptions for gabapentin and cyclobenzaprine. (Tr. 343-44.)

On May 27, 2020, Ms. Tuttle presented to Dr. Bihl for follow up. (Tr. 322.) She

reported her arthritis symptoms were well controlled. (Id.) She continued to report neuropathy

related pain and sacroiliac joint pain, but said muscle relaxers helped with her sacroiliac joint

pain. (Id.) Vitamin B12 deficiency was noted, but Ms. Tuttle reported improvement in her

fatigue. (Id.) She requested a referral to podiatry because she was in need of new inserts. (Tr.

323.) Examination findings were unremarkable. (Tr. 324.) Dr. Bihl continued to prescribe

gabapentin for neuropathy and cyclobenzaprine for sciatic nerve pain / muscle spasms, and

referred Ms. Tuttle to podiatry for her foot pain. (Tr. 324-25.)

On June 2, 2020, Ms. Tuttle presented to Michael G. Swiatek, DPM, at Avita Galion Foot

& Ankle Specialist for evaluation and treatment of neuropathic pain and painful digital nail

formations. (Tr. 588.) She reported not knowing if her neuropathy was related to her Marfan

Syndrome. (Id.) She also reported sciatic issues, but said the neuropathy started before those

issues. (Id.) She was taking her gabapentin as needed, rather than as scheduled, but noted that

she was going to try to take it as scheduled. (Id.) She said her neuropathy was progressing from

her feet to her ankles, and that her neuropathy-related pain was worse at night. (Id.) She also

reported numbness. (Tr. 589.) She said her orthotics were about three years old and broken

down and she was interested in a new pair. (Tr. 588.) On examination, Dr. Swiatek noted

decreased sharp/dull sensation bilaterally to the level of the ankle and diminished protective

sensations with a SWMF test to the level of the ankle. (Tr. 590.) He noted mild pain to the heels

bilaterally at the insertion of the plantar fascia. (Id.) Muscle strength in the bilateral lower

extremities was 5/5 and there was appropriate muscle tone and symmetry. (Id.) Dr. Swiatek

referred Ms. Tuttle to neurology for evaluation of her neuropathy and provided a prescription for

custom orthotics for her foot pain, neuropathy, and plantar fasciitis. (Id.)

On June 11, 2020, Ms. Tuttle presented to Kim E. Brown, P.T., at Avita Health Physical

Therapy for an ankle / foot orthotics evaluation. (Tr. 276.) She reported wearing orthotics for

five years for neuropathy and plantar fasciitis bilaterally. (Id.) She felt better when wearing her

orthotics, but said her current pair was torn up. (Id.) She described morning soreness until she

warmed up, and said her neuropathy symptoms were worse at night. (Id.) She reported her

current pain level was a 2/10, with her pain ranging from 1-9/10. (Id.) She was independent

with her activities of daily living, and she regularly gardened. (Tr. 277.) But she reported

diminished ability to ambulate and difficulty performing her prior level of exercise, travel, and/or

recreational activities. (Id.) On examination, Ms. Tuttle’s range of motion was abnormal for

rearfoot inversion and forefoot inversion. (Tr. 278.) She had excessive forefoot mobility and

abnormal plantar fascia testing. (Id.) PT Brown recommended that Ms. Tuttle be fitted for

custom orthotics (Tr. 280), and she was fitted on July 10, 2020 (Tr. 275).

On August 3, 2020, Ms. Tuttle presented to Robert T. Woodruff, M.D., at AVI ONT

Neurology, for evaluation of her neuropathy. (Tr. 572.) She reported an eight-year history of

progressive polyneuropathy and a diagnosis of Marfan Syndrome at age twelve. (Id.) She

reported numbness, paresthesia, and burning in her feet since 2012, which moved into her lower

limbs over time. (Id.) She said her symptoms were worse at night, with prolonged standing and

walking, or when standing on concrete. (Id.) Her feet felt better when she wore shoes, as

opposed to being barefoot. (Id.) She reported taking 300 mg gabapentin in the morning and

afternoon and 600 mg in the evening, but said the medication was not helping like it had in the

past. (Id.) Her physical examination revealed long feet with mild to moderately high arches,

sensory deficit, decreased Achilles reflexes, and loss of pinprick eight inches above the ankle.

(Tr. 576.) Her extensor digitorum brevis muscles (EDBs) were atrophic, and she could not

wiggle her toes. (Id.) Her coordination was intact, her gait was normal, and she could heel and

toe walk, but she had difficulty tandem walking. (Id.) Ms. Tuttle was diagnosed with sensory

polyneuropathy and neuropathic pain due to polyneuropathy. (Tr. 578.) Dr. Woodruff suspected

that Ms. Tuttle’s neuropathy was related to connective tissue disease (Marfan Syndrome). (Id.)

He recommended an EMG of the lower limbs. (Id.) He also recommended that she slowly

increase the gabapentin to 600 mg three times a day. (Id.) Ms. Tuttle’s August 13, 2020 EMG

and nerve conduction study of the lower extremities was abnormal and revealed “a severe,

symmetric, length-dependent, axonal, sensorimotor polyneuropathy.” (Tr. 546-51.)

On September 2, 2020, Ms. Tuttle returned to see podiatrist Dr. Swiatek. (Tr. 538.) As

to her neuropathic pain, she reported doing well with a topical cream and said her neurologist

had increased her gabapentin; her new orthotics were also helping. (Id.) Her review of systems

was positive for numbness and tingling in her feet. (Tr. 539.) On physical examination, Dr.

Swiatek noted decreased sharp/dull sensation bilaterally to the level of the ankle and diminished

protective sensations with SWMF to the level of the ankle. (Id.) But he also noted normal

sensation to light touch and normal muscle mass in the lower extremity and foot bilaterally. (Tr.

539-40.) Ms. Tuttle was able to heel and toe walk and rise from a seated position unassisted.

(Tr. 540.) She had normal muscle strength and appropriate muscle tone in the lower legs, ankles,

and feet. (Tr. 540.) Dr. Swiatek recommended that she continue the topical cream for

neuropathy and wear her orthotics for her foot pain, neuropathy, and plantar fasciitis. (Id.)

ii. Records After the Date Last Insured

On November 2, 2020. Ms. Tuttle returned to Dr. Woodruff for evaluation and

management of axonal polyneuropathy, after seeing him three months earlier in August. (Tr.

532.) She reported that the increase dosage of gabapentin helped but she was still having pain in

her feet. (Id.) She also reported intermittent low back pain for which she took Flexeril at

bedtime. (Id.) She complained of not being able to perform as much physical work as she had in

the past. (Id.) On examination, Dr. Woodruff noted motor weakness (4/5 DF weakness

bilaterally) and an antalgic gait pattern. (Tr. 536.) Ms. Tuttle’s diagnosis was polyneuropathy in

Marfan Syndrome. (Tr. 537.) Dr. Woodruff recommended adding 30 mg Cymbalta daily for

neuropathic pain. (Id.) Ms. Tuttle stated she would discuss it with her daughter who was a

nurse. (Id.) Dr. Woodruff advised Ms. Tuttle to follow up in Spring 2021. (Id.)

On November 23, 2020, Ms. Tuttle followed up with Dr. Bihl. (Tr. 529-31.) She

continued to report well-controlled arthritic symptoms, with bilateral neuropathic pain in the feet

and sacroiliac joint pain. (Tr. 529.) Examination findings were unremarkable. (Tr. 530.)

Ms. Tuttle returned to Dr. Swiatek on December 9, 2020. (Tr. 525.) She reported that

her neuropathic pain she was doing well with the pain cream, but she needed a refill. (Id.) She

said that her orthotics were “really helping.” (Id.) Review of systems was positive for numbness

and tingling in the feet. (Tr. 526.) On examination, Dr. Swiatek noted decreased sharp/dull

sensation bilateral to the level of the ankle. (Tr. 527.) Protective sensations were diminished

with SWMF to the level of the ankle. (Id.) There was normal sensation to light touch bilaterally

and normal muscle mass, tone, and strength in the lower extremities, and Ms. Tuttle was able to

heel and toe walk with ease and rise from a seated position unassisted. (Id.) Dr. Swiatek

provided a neuropathy cream refill and encouraged Ms. Tuttle to wear her orthotics daily. (Id.)

On March 12, 2021, Ms. Tuttle saw Dr. Bihl for an acute sick visit for congestion that

was conducted via video due to the pandemic. (Tr. 523-24.)

Ms. Tuttle returned to Dr. Woodruff on April 29, 2021. (Tr. 291.) She was taking 300

mg gabapentin three times daily and had added 30 mg Cymbalta once daily, but she reported that

she was still in “quite a bit of pain.” (Id.) She described a “ripping or tearing like pain in her

calves.” (Id.) On examination, Ms. Tuttle’s gait and station were normal, with normal muscle

strength and tone in all extremities. (Tr. 293.) She was able to walk easily, and she could do

tandem gait, walk on her heels, and walk on her toes. (Id.) Reflexes were 2+ in the upper limbs

and knees but absent at the ankles. (Id.) Ms. Tuttle’s diagnosis was Marfan Syndrome with

painful, sensory polyneuropathy. (Id.) Although Ms. Tuttle expressed concern that her

neuropathy was rapidly advancing, Dr. Woodruff indicated he was not seeing “significant

clinical worsening”; due to reported increased pain, he increased Cymbalta to 60 mg daily. (Id.)

On July 20, 2021, Ms. Tuttle returned to Dr. Woodruff for follow up. (Tr. 288.) She

reported that the increase in Cymbalta helped with her discomfort and pain in her feet and lower

legs, but she was still having trouble in the early evenings. (Id.) She also reported more fatigue

and less stamina when walking, and she reported using a cane on occasion. (Id.) On

examination, her muscle strength and tone in all extremities was normal. (Tr. 290.) She walked

“slowly and slightly with an unsteady pattern.” (Id.) Her diagnosis was idiopathic progressive

polyneuropathy. (Id.) Dr. Woodruff increased Ms. Tuttle’s gabapentin to 600 mg four times a

day and discussed adding 30 mg of Cymbalta in the evening if the gabapentin did not help with

her early evening pain. (Id.) At Ms. Tuttle’s request, Dr. Woodruff wrote Ms. Tuttle a handicap

prescription. (Id.)

On August 12, 2021, Ms. Tuttle saw Dr. Bihl for a video visit due to left ankle pain. (Tr.

511.) She was not certain of the cause of the injury, but she noted that her ankle gave out at

times due to her neuropathy. (Id.) X-rays of the left ankle were ordered. (Tr. 512.)

On September 9, 2021, Ms. Tuttle presented to Dr. Swiatek regarding pain in her right

ankle. (Tr. 505.) She described her pain as sharp and sometimes pulling with swelling. (Id.)

She said that “sitting and resting [did] seem to help and that walking/activity increase[d] the

pain.” (Id.) She also reported sleep disturbance due to her pain. (Tr. 506.) She said Dr. Bihl

had ordered an x-ray and prescribed prednisone for the issue.2 (Tr. 505.) On examination, Ms.

2 The records from Ms. Tuttle’s August 2021 visit with Dr. Bihl show she reported an injury to her left ankle. (Tr.

511.) During her September 2021 visit with Dr. Swiatek, she complained of right ankle pain, with reports of right

ankle x-rays from August 2021. (Tr. 507.) Thus, it is not clear whether there were two separate injuries or whether

the notations to the left ankle in the August 2021 record was incorrect and the injury was to the right ankle.

Tuttle’s gross and light sensations were intact in her lower extremities, with normal muscle mass

in the lower extremities and feet. (Tr. 507.) Dr. Swiatek noted pain to palpation of the medial

aspect of the right ankle in the area of the posterior tibial tendon, with positive pain with ankle

joint dorsiflexion, eversion, and inversion eversion. (Id.) No pain was noted in the area of the

insertion of the ATFL ankle ligaments. (Id.) No pain was noted on palpation to the base of the

5th metatarsal and posterior tibial tendon strength was graded at 4/5. (Id.) Ms. Tuttle was

diagnosed with posterior tibial tendinitis of the right lower extremity and right foot pain. (Id.)

She was prescribed diclofenac and a brace to be worn for four to eight weeks, and she was

advised to rest and elevate her foot while icing the affected area. (Tr. 507-08.)

On November 9, 2021, Ms. Tuttle returned to Dr. Woodruff for follow up. (Tr. 284.)

She reported that increasing her medication to 600 mg of gabapentin four times a day and to 60

mg of Cymbalta in the morning and 30 mg of Cymbalta in the evening “really helped the

discomfort in her feet.” (Id.) However, she had recently suffered a partial tendon tear in her

plantar flexors of her right ankle and was scheduled for surgery in about a month. (Id.) On

examination, Ms. Tuttle had difficulty ambulating due to a walking boot and poor balance. (Tr.

286.) Dr. Woodruff’s impression was that Ms. Tuttle’s condition–– idiopathic progressive

polyneuropathy––was stable on the aggressive symptomatic plan of 600 mg gabapentin four

times a day, 60 mg Cymbalta daily, and 30 mg Cymbalta in the evening. (Tr. 287.) He

recommended follow up in six months or as needed. (Id.)

On November 22, 2021, Ms. Tuttle saw Dr. Bihl for a preoperative evaluation. (Tr. 483.)

She was cleared for right ankle surgery. (Tr. 487.) On December 10, 2021, Ms. Tuttle

underwent right ankle surgery. (Tr. 457-69.) Following surgery, she was instructed to keep her

foot elevated while sitting or sleeping with no weight bearing for three weeks. (Tr. 457.)

On May 6, 2022, Ms. Tuttle saw Dr. Bihl. (Tr. 893-97.) She continued to complain of

neuropathic pain in her feet and sacroiliac joint pain. (Tr. 894-95.) She also complained of

palpitations that had been occurring once or twice a month at random times without activity for

about a year. (Tr. 894.) Examination findings were unremarkable. (Tr. 896.)

On October 21, 2022, Ms. Tuttle returned to Dr. Bihl. (Tr. 801.) She continued to report

neuropathic pain in her feet. (Id.) She also reported edema in her right foot due to her surgery.

(Id.) She reported pain in her left thumb that had been ongoing for months and palpitations that

started the other day. (Tr. 802.) She said she felt “out of rhythm” and “dizzy” since the

palpitations started. (Id.) Examination findings were unremarkable. (Tr. 804.) Dr. Bihl

recommended a Holter monitor. (Tr. 805.) The impression from the 12-day Holter monitor was

unremarkable, “with only 2 episodes of 3–5 beat PAT one of which symptomatic. Other two

symptoms occurred during sinus rhythm. Rare PAC, PVC.” (Tr. 775.)

When Ms. Tuttle saw Dr. Bihl on April 21, 2023, she presented with complaints of pain

in her feet and sacroiliac joints that were similar to prior reports of pain. (Tr. 722-23.)

Examination findings were unremarkable. (Tr. 724.)

2. Opinion Evidence

i. Treating Source

On August 3, 2023, Adam Bihl, M.D., of Avita Ontario Family Practice provided a letter,

stating:

Carla Tuttle is a patient of mine and was under my care for her neuropathy from

2015 to 2020. Please take in to consideration the following recommendations: Rest

and elevate feet waist level or higher for swelling and pain. Please contact the

office. . . for any further questions.

(Tr. 1848.)

ii. State Agency Medical Consultants

On April 19, 2022, state agency medical consultant, Linda Hall, M.D., completed a

Physical RFC Assessment, opining that Ms. Tuttle could: lift and/or carry 20 pounds

occasionally and 10 pounds frequently; stand and/or walk for a total of 4 hours in an 8-hour

workday; sit for a total of about 6 hours in an 8-hour workday; occasionally operate foot controls

with BLE (bilateral lower extremities); never climb ladders, ropes, or scaffolds; occasionally

climb ramps/stairs, balance, stoop, kneel, crouch, and crawl; and avoid all exposure to hazards.

(Tr. 61-62.) Dr. Hall explained the exertional limitations of 4 hours standing and walking in an

8-hour day and occasional BLE foot controls were “[d]ue to documented severe, symmetric,

length-dependent, axonal, polyneuropathy on EMG, w/ 4/5 DF weakness, decreased BLE

sensation, and antalgic gait pattern and neck, back, and hip pain.” (Tr. 61.) Dr. Hall explained

the postural limitations were “[d]ue to neck, back, and joint pain and documented peripheral

neuropathy w/ decreased BLE sensation, mild 4/5 DF, and antalgic gait.” (Tr. 62.) With respect

to the environmental limitation that Ms. Tuttle avoid all exposure to hazards, Dr. Hall explained

that Ms. Tuttle could have no exposure to “hazardous heights” and could not “operat[e]

hazardous machinery requiring use of foot controls due to peripheral neuropathy.” (Id.)

State agency medical consultant Elizabeth Das, M.D., agreed with Dr. Hall’s Physical

RFC Assessment on reconsideration on September 12, 2022. (Tr. 69-71.)

C. Hearing Testimony

1. Plaintiff’s Testimony

Ms. Tuttle testified in response to questioning by the ALJ and her counsel at the hearing

on August 23, 2023. (Tr. 38-51.) The ALJ and Ms. Tuttle’s counsel reminded Ms. Tuttle that

the period of time that she should focus on during her testimony was between April 1, 2015, and

September 30, 2020. (Tr. 41, 43.)

Ms. Tuttle reported that she stopped working in April 2015 because she was having a lot

of pain during the workday, she was not able to anything once she was home, and she was

missing a lot of work due to pain in her feet and legs. (Tr. 42.) She said she “just got to the

point where [she] just couldn’t do it anymore.” (Id.) She was hoping that her pain would get

better, but she did not initially realize there was no “cure for [her neuropathy diagnosis],”

because it “just progresses” and “doesn’t get better.” (Id.)

Ms. Tuttle testified that she was prescribed gabapentin and Cymbalta for neuropathy in

her lower extremities. (Tr. 42.) As far as other treatment modalities, she said she had to elevate

her legs several times a day; if she did not do so she would “pretty much [be] down for at least

three days and [could not] do anything really.” (Id.) She said there really was no other treatment

to help with the neuropathy and associated pain. (Id.) She had to have one surgery to repair a

torn tendon in her right ankle that occurred when she tripped due to drop foot from her

neuropathy. (Tr. 43.) In addition to neuropathy, Ms. Tuttle said she also had Marfan syndrome,

which was a connective tissue disorder that affected her whole body. (Tr. 44-45.) At times, the

condition caused her lower back to go out. (Tr. 44.) When that happened, she would usually be

down for at least a week, and she would have to take pain medication or receive shots and

usually ended up in the emergency room. (Id.)

Ms. Tuttle reported having numbness and burning in her feet since 2012, which had

gradually worsened and moved into her legs. (Tr. 45.) Since September 2020, she said her

neuropathy-related pain increased drastically, noting that her most recent EMG showed her

neuropathy was up to her knees. (Id.) She said her gabapentin dose was previously 600 mg but

it had been increased to the maximum of 2400 mg. (Tr. 45-46.) Prior to September 2020, she

said medication side effects included tiredness and drowsiness, which affected her ability to

recall things at times. (Tr. 46.) She said she could stand or walk for about thirty minutes before

needing to elevate her feet to waist level or higher for thirty minutes. (Tr. 44, 47-48.) She also

reported difficulty sitting for longer than thirty minutes without elevating her legs because it

caused pain. (Tr. 47, 48.) Even when her feet were elevated, she said it did not take her pain

away; it just relieved it. (Tr. 47.) She estimated elevating her feet five to six times during the

day for thirty minutes to two hours at a time. (Tr. 49-50.) She was able to drive, but had

someone else drive her if she had to drive for “long periods” like an hour. (Tr. 48-49.) She

estimated being able to lift about twenty-five to thirty pounds. (Tr. 49.)

2. Vocational Expert’s Testimony

A Vocational Expert (“VE”) also testified at the hearing. (Tr. 51-55.) The VE testified

that Ms. Tuttle’s past relevant work as an ultrasound technician was a skilled, light exertional

position, performed by Ms. Tuttle at the medium exertional level. (Tr. 52.)

In response to the ALJ’s second hypothetical, the VE testified that a hypothetical

individual of Ms. Tuttle’s age, education, and work experience, with the functional limitations

described in the ALJ’s RFC determination (Tr. 20, 53, 54), could perform sedentary positions in

the national economy such as: order clerk, electronic inspector, and charge account clerk. (Tr.

53-54.) For her third hypothetical, the ALJ asked the VE to assume the same limitations as the

second hypothetical with the following additional limitations: the individual would be able to

understand, remember, and carry out only simple instructions; the individual could have

occasional interaction with the public, coworkers, and supervisors; and the individual would

need to have the ability to elevate her feet to waist level throughout the day or while in position.

(Tr. 54.) The VE testified that there would be no competitive work available for such an

individual. (Tr. 54-55.) The VE also testified that the tolerance for off task behavior was no

more than ten percent of loss production and no more than two absences per month. (Tr. 55.)

III. Standard for Disability

Under the Social Security Act, 42 U.S.C. § 423(a), eligibility for benefit payments

depends on the existence of a disability. “Disability” is defined as the “inability to engage in any

substantial gainful activity by reason of any medically determinable physical or mental

impairment which can be expected to result in death or which has lasted or can be expected to

last for a continuous period of not less than 12 months.” 42 U.S.C. § 423(d)(1)(A).

An individual shall be determined to be under a disability only if his physical or

mental impairment or impairments are of such severity that he is not only unable to

do his previous work but cannot, considering his age, education, and work

experience, engage in any other kind of substantial gainful work which exists in the

national economy[.]

42 U.S.C. § 423(d)(2)(A).

To make a determination of disability under this definition, an ALJ is required to follow a

five-step sequential analysis set out in agency regulations, summarized as follows:

1. If the claimant is doing substantial gainful activity, he is not disabled.

2. If the claimant is not doing substantial gainful activity, his impairment must

be severe before he can be found to be disabled.

3. If the claimant is not doing substantial gainful activity, is suffering from a

severe impairment that has lasted or is expected to last for a continuous

period of at least twelve months, and his impairment meets or equals a listed

impairment, the claimant is presumed disabled without further inquiry.

4. If the impairment does not meet or equal a listed impairment, the ALJ must

assess the claimant’s residual functional capacity and use it to determine if

the claimant’s impairment prevents him from doing past relevant work. If

the claimant’s impairment does not prevent him from doing his past relevant

work, he is not disabled.

5. If the claimant is unable to perform past relevant work, he is not disabled if,

based on his vocational factors and residual functional capacity, he is

capable of performing other work that exists in significant numbers in the

national economy.

20 C.F.R. § 404.1520; see also Bowen v. Yuckert, 482 U.S. 137, 140–42 (1987). Under this

sequential analysis, the claimant has the burden of proof at Steps One through Four. See Walters

v. Comm’r of Soc. Sec., 127 F.3d 525, 529 (6th Cir. 1997). The burden shifts to the

Commissioner at Step Five to establish whether the claimant has the Residual Functional

Capacity (“RFC”) and vocational factors to perform other work available in the national

economy. Id.

IV. The ALJ’s Decision

In her October 9, 2023, decision, the ALJ made the following findings:3

1. The claimant last met the insured status requirements of the Social Security

Act on September 30, 2020. (Tr. 19.)

2. The claimant did not engage in substantial gainful activity during the

period from her alleged onset date of April 1, 2015, through her date last

insured of September 30, 2020. (Id.)

3. The claimant had the following severe impairments through the date last

insured: peripheral neuropathy, Marfan syndrome, osteoarthritis, and

plantar fasciitis. (Tr. 19.) The claimant also had non-severe impairments

physical impairments; there were no medically determinable mental health

impairments. (Tr. 19-20.)

4. Through the date last insured, the claimant did not have an impairment or

combination of impairments that met or medically equaled the severity of

one of the listed impairments in 20 C.F.R. Part 404, Subpart P, Appendix

1. (Tr. 20.)

5. Through the date last insured, the claimant had the residual functional

capacity to perform sedentary work as defined in 20 CFR 404.1567(a)

except the claimant can occasionally operate foot controls with the bilateral

lower extremities; can never climb ladders, ramps, or scaffolds; can

occasionally climb ramps and stairs; can occasionally balance, stoop,

3 The ALJ’s findings are summarized.

kneel, crouch, and crawl; must avoid exposure to all hazards, including

unprotected heights, dangerous machinery, and machinery requiring use of

foot controls in general. (Tr. 20-25.)

6. Through the date last insured, the claimant was unable to perform any past

relevant work. (Tr. 25.)

7. The claimant was born in 1971, and was 48 years old, defined as a younger

individual age 18-44, on the date last insured, and she subsequently

changed age category to a younger individual age 45-49. (Id.)

8. The claimant has at least a high school education. (Id.)

9. Transferability of job skills is not material to the determination of

disability. (Id.)

10. Through the date last insured, considering claimant’s age, education, work

experience, and residual functional capacity, there were jobs that existed

in significant numbers in the national economy that the claimant could

have performed, including order clerk, electronic inspector, and charge

account clerk. (Tr. 25-26.)

Based on the foregoing, the ALJ found Ms. Tuttle was not under a disability from April

1, 2015, the alleged onset date, through September 30, 2020. (Tr. 26.)

V. Plaintiff’s Arguments

Ms. Tuttle presents three arguments in her sole assignment of error. (ECF Doc. 9, pp. 9-

23; ECF Doc. 13.) First, she argues the ALJ erred in evaluating Dr. Bihl’s opinion. (ECF Doc.

9, pp. 12-17; ECF Doc. 13, pp. 1-4.) Second, she argues the ALJ erred in evaluating her

subjective allegations. (ECF Doc. 9, pp. 17-22; ECF Doc. 13, pp. 4-6.) Third, she argues the

RFC is not supported by substantial evidence. (ECF Doc. 9, pp. 22-23; ECF Doc. 13, p. 6.)

VI. Law & Analysis

A. Standard of Review

A reviewing court must affirm the Commissioner’s conclusions absent a determination

that the Commissioner has failed to apply the correct legal standards or has made findings of fact

unsupported by substantial evidence in the record. See Blakley v. Comm’r of Soc. Sec., 581 F.3d

399, 405 (6th Cir. 2009) (“Our review of the ALJ's decision is limited to whether the ALJ

applied the correct legal standards and whether the findings of the ALJ are supported by

substantial evidence.”).

When assessing whether there is substantial evidence to support the ALJ’s decision, the

Court may consider evidence not referenced by the ALJ. Heston v. Comm’r of Soc. Sec., 245

F.3d 528, 535 (6th Cir. 2001). “Substantial evidence is more than a scintilla of evidence but less

than a preponderance and is such relevant evidence as a reasonable mind might accept as

adequate to support a conclusion.” Besaw v. Sec’y of Health & Hum. Servs., 966 F.2d 1028, 1030

(6th Cir. 1992) (quoting Brainard v. Sec’y of Health & Hum. Servs., 889 F.2d 679, 681 (6th Cir.

1989)). The Commissioner’s findings “as to any fact if supported by substantial evidence shall

be conclusive.” McClanahan v. Comm’r of Soc. Sec., 474 F.3d 830, 833 (6th Cir. 2006) (citing

42 U.S.C. § 405(g)). “‘The substantial-evidence standard . . . presupposes that there is a zone of

choice within which the decisionmakers can go either way, without interference by the courts.’”

Blakley, 581 F.3d at 406 (quoting Mullen v. Bowen, 800 F.2d 535, 545 (6th Cir. 1986)).

Therefore, a court “may not try the case de novo, nor resolve conflicts in evidence, nor decide

questions of credibility.” Garner v. Heckler, 745 F.2d 383, 387 (6th Cir. 1984). Even if

substantial evidence supports a claimant’s position, a reviewing court cannot overturn the

Commissioner’s decision “so long as substantial evidence also supports the conclusion reached

by the ALJ.” Jones v. Comm’r of Soc. Sec., 336 F.3d 469, 477 (6th Cir. 2003).

Although an ALJ decision may be supported by substantial evidence, the Sixth Circuit

has explained that the “‘decision of the Commissioner will not be upheld where the SSA fails to

follow its own regulations and where that error prejudices a claimant on the merits or deprives

the claimant of a substantial right.’” Rabbers v. Comm'r Soc. Sec. Admin., 582 F.3d 647, 651

(6th Cir. 2009) (quoting Bowen v. Comm’r of Soc. Sec., 478 F.3d 742, 746 (6th Cir. 2007) (citing

Wilson v. Comm’r of Soc. Sec., 378 F.3d 541, 546–547 (6th Cir. 2004))). A decision will also

not be upheld where the Commissioner’s reasoning does not “build an accurate and logical

bridge between the evidence and the result.” Fleischer v. Astrue, 774 F. Supp. 2d 875, 877 (N.D.

Ohio 2011) (quoting Sarchet v. Chater, 78 F.3d 305, 307 (7th Cir. 1996)).

B. Sole Assignment of Error: The ALJ Properly Evaluated the Medical Opinions,

Subjective Allegations, and RFC Limitations

In her sole assignment of error, Ms. Tuttle argues the ALJ: failed to properly evaluate Dr.

Bihl’s opinion (ECF Doc. 9, pp. 12-17; ECF Doc. 13, pp. 1-4); failed to properly evaluate her

subjective allegations (ECF Doc. 9, pp. 17-22; ECF Doc. 13, pp. 4-6); and assessed an RFC that

is not supported by substantial evidence (ECF Doc. 9, pp. 22-23; ECF Doc. 13, p. 6). All three

arguments center around an assertion that ALJ should have adopted an RFC allowing for Ms.

Tuttle to elevate her legs throughout the day. Each argument is addressed in turn below.

1. The ALJ Properly Evaluated Dr. Bihl’s Opinion

Ms. Tuttle argues that the ALJ “failed to apply the consistency and supportability factors

to the opinion of long-term treating physician, Adam J. Bihl, M.D.,” as the regulations require.

(ECF Doc. 9, p. 9.) The Commissioner responds that the ALJ “reasonably discounted Dr. Bihl’s

opinion because it lacked both supportability and consistency.” (ECF Doc. 12, pp. 5-6.)

The Social Security Administration’s (“SSA”) regulations for evaluating medical opinion

evidence require ALJs to evaluate the “persuasiveness” of medical opinions “using the factors

listed in paragraphs (c)(1) through (c)(5)” of the regulation. 20 C.F.R. § 404.1520c(a). The five

factors to be considered are supportability, consistency, relationship with the claimant,

specialization, and other factors. 20 C.F.R. § 404.1520c(c)(1)-(5). The most important factors

are supportability and consistency. 20 C.F.R. §§ 404.1520c(a), 404.1520c(b)(2). ALJs must

explain how they considered consistency and supportability, but need not explain how they

considered the other factors. 20 C.F.R. § 404.1520c(b)(2).

As to supportability, the regulations state: “The more relevant the objective medical

evidence and supporting explanations presented by a medical source are to support his or her

medical opinion(s) or prior administrative medical finding(s), the more persuasive the medical

opinions or prior administrative medical finding(s) will be.” 20 C.F.R. § 404.1520c(c)(1). In

other words, “supportability” is the extent to which a medical source’s own objective findings

and supporting explanations substantiate or support the findings in the opinion.

As to consistency, the regulations state: “The more consistent a medical opinion(s) or

prior administrative medical finding(s) is with the evidence from other medical sources and

nonmedical sources in the claim, the more persuasive the medical opinion(s) or prior

administrative medical finding(s) will be.” 20 C.F.R. § 404.1520c(c)(2). In other words,

“consistency” is the extent to which a medical source’s opinion findings are consistent with

evidence from other medical and nonmedical sources in the record.

The ALJ analyzed the persuasiveness of Dr. Bihl’s medical opinion as follows:

In correspondence dated August 3, 2023, Adam Bihl, M.D., noted that the claimant

has been under his care for her neuropathy from 2015 through 2020 and that he

recommended rest and elevating feet to waist level or higher for swelling and pain

[]. The undersigned has found this assessment unpersuasive. There is no objective

evidence cited by Dr. Bihl to support the extent of the limitations assessed.

Furthermore, review of the record above does not establish foundation for or

medical support for either of Dr. Bihl’s allowances.

(Tr. 24-25 (emphasis added) (internal citation omitted).)

Ms. Tuttle argues first that the ALJ inadequately addressed the “supportability” of Dr.

Bihl’s opinion—i.e., the extent to which Dr. Bihl’s own objective findings and supporting

explanations substantiate or support the findings in his opinion—because the ALJ: (1) “failed to

provide any explanation as to why” Dr. Bihl’s supporting explanations were insufficient; and (2)

“failed to compare the content of Dr. Bihl’s treatment notes to his opinion.” (ECF Doc. 9, p. 13.)

Neither argument is borne out by the record. As to “supporting explanations,” the ALJ explicitly

highlighted Dr. Bihl’s failure to cite to any “objective evidence . . . to support the extent of the

limitations assessed.” (Tr. 24-25.) And as to Dr. Bihl’s treatment notes, the ALJ specifically

summarized many of those records (Tr. 21-23) before finding “the record above does not

establish foundation for or medical support for either of Dr. Bihl’s allowances” (Tr. 25), those

allowances being the reported need for rest and elevation of feet due to swelling and pain (Tr.

24). The treatment records of Dr. Bihl summarized by the ALJ included:

• Visits from March and September 2016 which “showed complaints of neuropathy,

although physical examination was entirely unremarkable,” with “[m]edication

management on a regimen including Gabapentin” (Tr. 21 (citing Tr. 260-68);

• A visit from November 2018 where Ms. Tuttle “ask[ed] for an increase in medication

for neuropathy symptoms in the feet,” “[p]hysical examination was entirely

unremarkable,” and she was “continued on Gabapentin” (Tr. 22 (citing Tr. 355-58));

• A visit from May 2019 where she “continued to endorse feet pain at bedtime,” but

“physical examination continued to show no significant findings” and her “regimen

of Gabapentin and Cyclobenzaprine was unchanged” (id. (citing Tr. 347-48)); and

• A visit from May 2020 which where Ms. Tuttle’s “[p]hysical examination was

unremarkable” and there were “no changes” in her “Gabapentin and muscle relaxer

regimen,” and she was referred to podiatry “to evaluate a request for new orthotic

inserts” (Tr. 22-23 (citing Tr. 322-25).

Dr. Bihl’s records, as summarized by the ALJ, thus reflected that Ms. Tuttle complained of

neuropathy symptoms in her feet over a period of years, but had consistently unremarkable

clinical examinations and treated her symptoms with Gabapentin, muscle relaxers, and orthotics.

Neither the ALJ’s summary nor the records themselves included recommendations for Ms. Tuttle

to rest or elevate her feet to alleviate swelling or pain from neuropathy. It is therefore reasonable

to conclude that the ALJ was supported by substantial evidence when she found the records she

previously summarized did not “establish foundation . . . or medical support for” requirements

that Ms. Tuttle rest or elevate her feet due to pain or swelling caused by neuropathy. (Tr. 25.)

Ms. Tuttle’s arguments that “[t]he ‘supporting explanations’ [are] one-half of the required

consideration under the supportability factor, and the supportability factor is not limited solely to

objective findings” (ECF Doc. 9, p. 13) do not change this analysis. The ALJ was required to

consider supportability, and provided an adequate explanation of her analysis. Regardless of

whether the evidence highlighted by Ms. Tuttle might alternately support a finding that Dr.

Bihl’s opinion was supportable, this Court cannot overturn the ALJ’s findings to the contrary “so

long as substantial evidence also supports the conclusion reached by the ALJ.” Jones, 336 F.3d

at 477. That is because “‘[t]he substantial-evidence standard . . . presupposes that there is a zone

of choice within which the decisionmakers can go either way, without interference by the

courts.’” Blakley, 581 F.3d at 406 (quoting Mullen, 800 F.2d at 545).

Ms. Tuttle’s argument that “it is unclear how the evidence does not support [Dr. Bihl’s]

opinion” because “the ALJ did not compare any of Dr. Bihl’s treatment notes to his opinion”

(ECF Doc. 9, p. 14) also does not change the analysis. Given that the ALJ’s summary of the

records (accurately) reflects conservative treatment, no abnormal clinical findings, and no

contemporaneous recommendations mirroring the limitations described in Dr. Bihl’s 2023

medical opinion—which post-dates the relevant treatment notes by at least three years—the ALJ

adequately explained her reasoning when she said the previously summarized treatment records

failed to establish a “foundation” or “medical support” for the recommendations in Dr. Bihl’s

opinion. Certainly, the ALJ was permitted to rely on information articulated earlier in a decision

to support her findings, and was not required to rearticulate that information in her later analysis.

See Crum v. Comm’r of Soc. Sec., 660 F. App’x 449, 457 (6th Cir. 2016); Bledsoe v. Barnhart,

165 F. App’x 408, 411 (6th Cir. 2006).

Ms. Tuttle also argues that the ALJ inadequately addressed the “consistency” of Dr.

Bihl’s opinion—i.e., the extent to which Dr. Bihl’s opinion findings are consistent with evidence

from other medical and nonmedical sources in the record—because her general reference to a

“review of the record above” did not explain “how Dr. Bihl’s opinion is inconsistent with the

record[.]” (ECF doc. 9, p. 14.) Ms. Tuttle acknowledges that Dr. Bihl’s own treatment records

“lacked objective findings,” but argues that “the treatment notes of multiple specialists contain

objective findings consistent with [her] symptoms and, ultimately, Dr. Bihl’s assessment of

limitations.” (Id. at p. 15.) While Ms. Tuttle is correct that other treatment notes contained

clinical findings consistent with neuropathy and decreased lower extremity sensation, the ALJ

clearly summarized and acknowledged those findings before evaluating Dr. Bihl’s opinion. (See

Tr. 21-23 (citing, e.g., Tr. 1688-89 (10/4/18, noting diminished sensation in both feet consistent

with neuropathy); Tr. 577 (8/3/20, noting sensory deficit with loss of pinprick 8” above each

ankle, inability to wiggle toes, and difficulty with tandem walk); & Tr. 546-49 (8/3/20 EMG

finding “severe, symmetric, length-dependent, axonal, sensorimotor polyneuropathy”).) Having

discussed those findings in detail earlier in her decision, the ALJ was not required to repeat the

discussion in her opinion analysis. See Crum, 660 F. App’x at 457. The undersigned also does

not find that additional explanation was needed to clarify the ALJ’s finding that the previously

summarized records did not establish a “foundation” or “medical support” for a recommendation

that Mr. Tuttle elevate her feet to address pain and swelling. While the records were consistent

with neuropathic pain and decreased sensation, none of the records summarized by the ALJ or

identified in Ms. Tuttle’s brief contained recommendations or instructions to elevate her feet.

As with the supportability analysis, the question before this Court is not whether the

evidence highlighted by Ms. Tuttle could support a finding that Dr. Bihl’s opinion was consistent

with other evidence in the record. This Court cannot overturn the ALJ’s findings to the contrary

“so long as substantial evidence also supports the conclusion reached by the ALJ.” Jones, 336

F.3d at 477. Here, it is evident that the ALJ considered the consistency of Dr. Bihl’s opinion

findings with other evidence in the record and provided an adequate explanation for her finding

that those records did not provide a foundation or medical support for any requirement that Ms.

Tuttle elevate her feet in the manner described in Dr. Bihl’s opinion.

Thus, having reviewed the ALJ decision as a whole, the undersigned concludes that the

ALJ articulated the basis for her persuasiveness findings in a manner that adequately explained

how she considered the factors of “consistency” and “supportability,” and that Ms. Tuttle has not

shown that the ALJ’s explanations or findings lacked the support of substantial evidence.

2. ALJ Properly Evaluated Plaintiff’s Subjective Allegations

In her second argument, Ms. Tuttle acknowledges that the ALJ’s written decision

“provided reasons” for discounting her subjective complaints, but argues that the reasons the

ALJ gave were “insufficient to explain why Plaintiff’s allegations are unsupported.” (ECF Doc.

9, p. 17.) The Commissioner responds that “[s]ubstantial evidence supports the ALJ’s

determination that Plaintiff’s symptoms were not entirely consistent with the record,” and more

specifically the ALJ’s finding “that the evidence did not support Plaintiff’s testimony about

having to elevate her feet to waist level.” (ECF Doc. 12, p. 8.)

Under the two-step process used to assess the limiting effects of a claimant’s symptoms,

a determination is first made as to whether there is an underlying medically determinable

impairment that could reasonably be expected to produce the claimant’s symptoms. See SSR 16-

3p, 82 Fed Reg. 49462, 49463 (Oct. 25, 2017); Rogers v. Comm’r of Soc. Sec., 486 F.3d 234,

247 (6th Cir. 2007) (citing 20 C.F.R. § 416.929(a)). If that requirement is met, the second step is

to evaluate the intensity and persistence of the claimant’s symptoms to determine the extent to

which they limit the claimant’s ability to perform work-related activities. See SSR 16-3p, 82 Fed

Reg. 49462, 49463; Rogers, 486 F.3d at 247. Relevant factors included daily activities, types

and effectiveness of medications, treatment received to address symptoms, and other factors

concerning a claimant’s functional limitations and restrictions due to pain or other symptoms.

See SSR 16-3p, 82 Fed. Reg. 49462, 49465-49466; 20 C.F.R. 404.1529(c)(3).

Here, the ALJ considered Ms. Tuttle’s subjective allegations and concluded that her

“medically determinable impairments could reasonably be expected to cause the alleged

symptoms,” but nevertheless found her “statements concerning the intensity, persistence and

limiting effects of th[o]se symptoms [were] not entirely consistent with the medical evidence and

other evidence in the record.” (Tr. 23-24.) In support of this finding, the ALJ explained:

Regarding the claimant’s medical conditions, the record reflects a history of

Marfan’s syndrome diagnosed in childhood. Records during the period at issue

reflected treatment for osteoarthritis and plantar fasciitis, with symptoms of

bilaterally lower extremity peripheral neuropathy. Despite the claimant’s subjective

reports, records during the period at issue show consistently conservative treatment

in the form of medication management and prescribed orthotic shoe inserts for pain.

Despite notations of diminished sensation to light touch in the bilateral feet in a

stocking pattern, the majority of physical examinations during the period at issue

were unremarkable with respect to any significant findings. At no time did the

claimant require inpatient hospitalization or surgical intervention for any of her

alleged impairments. The record did not support the extent of the claimant’s alleged

sitting, standing, or walking restrictions as noted during testimony, reported of the

extent of leg elevation as noted during testimony, or difficulties with lifting. There

is no indication that the claimant has required any assistive devices of any type for

balance or ambulation, and no significant side effects from medications. Therefore,

after consideration of the medical evidence of record during the period at issue, the

undersigned has found the claimant capable of sedentary work with the claimant

able to occasionally operate foot controls with the bilateral lower extremities; can

never climb ladders, ramps, or stairs; occasionally climb ramps and stairs, and

occasionally balance as that term is defined in the Dictionary of Occupational Titles

(DOT); can occasionally stoop, kneel, crouch, and crawl; must avoid exposure to

all hazards, including unprotected heights, dangerous machinery, and those

requiring use of foot controls.

(Tr. 24.)

Ms. Tuttle argues that the ALJ’s explanation was inadequate because she: (1) failed to

explain how “conservative treatment” was inconsistent with the allegations; (2) failed to explain

how clinical findings of reduced sensation were inconsistent with the allegations; and (3)

discussed the need for an assistive device when Ms. Tuttle did not allege that she needed an

assistive device. (ECF Doc. 9, pp. 19-22.) These arguments will be addressed in turn.

In her first argument, Ms. Tuttle draws an analogy between Ms. Tuttle’s neuropathy and

cases involving the treatment of fibromyalgia, arguing it is irrelevant that her treatment did not

involve “inpatient hospitalization or surgical intervention” because “[i]t is unclear how Plaintiff

could treat more aggressively for her severe impairments.” (Id. at p. 19.) But she also asserts

that she later received “surgery for ‘the drop foot from the neuropathy’” after the expiration of

her date last insured. (Id. at p. 20 (citing Tr. 43).) The regulations advise that one factor to be

considered in evaluating the intensity, persistence, and limiting effects of a person’s symptoms is

“[t]reatment, other than medication, an individual receives or has received for relief of pain or

other symptoms.” SSR 16-3p, 82 FR at 49466; see 20 C.F.R. § 404.1529(c)(3)(v). Thus, it was

wholly appropriate for the ALJ to observe—among other factors—that “records during the

period at issue show consistently conservative treatment in the form of medication management

and prescribed orthotic shoe inserts for pain,” and that “[a]t no time did the claimant require

inpatient hospitalization or surgical intervention for any of her alleged impairments.” (Tr. 24.)

In her second argument, Ms. Tuttle challenges the ALJ’s observation that: “Despite

notations of diminished sensation to light touch in the bilateral feet in a stocking pattern, the

majority of physical examinations during the period at issue were unremarkable with respect to

any significant findings.” (Tr. 24.) Specifically, she argues that the ALJ failed to explain how

the clinical findings of diminished sensation were inconsistent with Ms. Tuttle’s subjective

allegations (ECF Doc. 9, p. 20), and also that it was “inaccurate” for the ALJ to say “the majority

of physical examination during the period at issue were unremarkable with respect to any

significant findings” (id. at p. 21 (quoting Tr. 24)).

As to the first issue, the ALJ acknowledged that Ms. Tuttle alleged she could stand or

walk for 30 minutes and sit for 30 minutes without elevating her legs, and that she kept her feet

elevated 5-6 times per day, for 30 minutes to two hours each time. (Tr. 21.) The ALJ then

concluded, after outlining the medical records (Tr. 21-23), that Ms. Tuttle’s conservative

treatment with medications and orthotics, with clinical findings of reduced sensation but

otherwise largely unremarkable findings, was inconsistent with the significant standing, walking,

sitting, and leg-elevation limitations alleged by Ms. Tuttle (Tr. 24). The ALJ adequately

explained why the balance of factors did not support Ms. Tuttle’s alleged level of limitation.

As to the second issue, Ms. Tuttle has failed to show that the ALJ was “inaccurate” or

otherwise mischaracterized the evidence when she said the “majority of physical examination

findings . . . were unremarkable.” (Tr. 24.) While Ms. Tuttle highlights abnormal findings from

a few examinations and an EMG in 2020 (see ECF Doc. 9, p. 21 (citing Tr. 576-78 (8/3/20

exam), 590 (6/2/20 exam), 278 (6/11/20 PT evaluation), 546-51 (8/13/20 EMG))), the ALJ

acknowledged those and other abnormal examination findings, but also identified numerous

examinations between 2016 and 2020 where the findings were unremarkable (Tr. 21-23).

Further, even those examinations with some abnormal findings—such as the October 2018 exam

that noted diminished sensation to light touch in the bilateral feet, downgoing plantar responses,

and mildly positive hip and SI joint provocative tests (Tr. 1689)—could be reasonably described

as having a “majority of physical examination findings” that were unremarkable (Tr. 24), like

normal lower extremity pulses, reflexes, and strength, and negative SLR and Spurling’s tests (Tr.

1689). The ALJ’s characterization of the “majority of physical examination findings” as

“unremarkable” thus did not amount to a misrepresentation of the evidentiary record.

In her final argument, Ms. Tuttle asserts that the ALJ relied on “irrelevant or factually

unsupported” reasons when she found: “There is no indication that the claimant has required any

assistive devices of any type for balance or ambulation.” (ECF Doc. 9, p. 22 (quoting Tr. 24).)

Since Ms. Tuttle did not allege that she used an assistive device, she asserts that this observation

did not “identify an inconsistency in the record.” (Id.) But the ALJ observed that Ms. Tuttle did

allege she could only stand or walk for 30 minutes. (Tr. 21.) The regulations advise that other

factors to be considered in evaluating the intensity, persistence, and limiting effects of a person’s

symptoms include: “[a]ny other factors concerning an individual’s functional limitations and

restrictions due to pain or other symptoms.” SSR 16-3p, 82 FR at 49466; see 20 C.F.R. §

404.1529(c)(3)(vii). Whether an individual who alleges that she could not stand or walk longer

than 30 minutes used an assistive device to help with standing or walking was an appropriate

consideration. Thus, it was not improper for the ALJ to consider whether Ms. Tuttle used or

required the use of an assistive device when assessing Ms. Tuttle’s subjective allegations.

Consistent with the regulations, the ALJ explicitly considered Ms. Tuttle’s medical

diagnoses, conservative treatment modalities, objective medical findings, and other factors

relevant her functional limitations before concluding that her subjective allegations were “not

entirely consistent with the medical evidence and other evidence in the record.” (Tr. 24.)

Nevertheless, the ALJ adopted a restrictive sedentary RFC with additional limitations in the use

of foot controls, climbing, postural positions, and exposure to hazards. (Id.) In this context, the

undersigned finds Ms. Tuttle has not met her burden to show that the ALJ’s analysis of her

subjective complaints failed to meet the regulatory standards. Instead, the ALJ weighed all of

the evidence, credited Ms. Tuttle’s subjective allegations to the extent she found them supported

by the record, and limited her to a sedentary RFC with additional limitations.

Having reviewed the ALJ decision as a whole, the undersigned concludes that the ALJ

considered the subjective allegations in the context of the record as a whole and adequately

articulated the basis for her related findings, and further that Ms. Tuttle has not shown that the

ALJ’s explanations or findings lacked the support of substantial evidence.

3. The RFC Finding is Supported by Substantial Evidence

In a cursory third argument, Ms. Tuttle asserts that the ALJ failed to adequately explain

the basis for her RFC limitations when she found the medical opinions of the state agency

medical consultants “unpersuasive” and adopted an RFC with “greater functional limitation[s].”

(ECF Doc. 9, pp. 22-23 (quoting Tr. 24).)4

A claimant’s “residual functional capacity is the most [she] can still do despite [her]

limitations.” 20 C.F.R. § 404.1545(a)(1). “The responsibility for determining a claimant’s

residual functional capacity rests with the ALJ, not a physician.” Poe v. Comm’r of Soc. Sec.,

342 F. App’x 149, 157 (6th Cir. 2009) (citing See 20 C.F.R. §§ 404.1546(c), 416.946(c)). An

ALJ assesses a claimant’s “residual functional capacity based on all the relevant evidence in

[the] case record.” 20 C.F.R. § 404.1545(a)(1). “[A]n ALJ does not improperly assume the role

4 To the extent Ms. Tuttle also intended to argue that a medical expert was needed to interpret “raw medical data” in

this case (ECF Doc. 9, p. 23), the undersigned finds the argument is underdeveloped and therefore waived. See

McPherson, 125 F.3d at 995-96.

of a medical expert by assessing the medical and non-medical evidence before rendering a

residual functional capacity finding.” Poe, 342 F. App’x at 157.

Here, the ALJ found Ms. Tuttle had the RFC to perform sedentary work with the

following additional limitations: occasionally operate foot controls with the bilateral lower

extremities; can never climb ladders, ramps, or scaffolds; can occasionally climb ramps and

stairs; can occasionally balance, stoop, kneel, crouch, and crawl; must avoid exposure to all

hazards, including unprotected heights, dangerous machinery, and machinery requiring use of

foot controls in general.5 (Tr. 20.)

When addressing the state agency medical consultant opinions, the ALJ explained:

The undersigned has considered the State agency medical consultant’s opinions

which initially found the claimant limited to a reduced range of light exertion work;

4-hours standing and/or walking; occasional climbing of ramps and stairs; never

climbing ladders, ropes, or scaffolds; occasional balancing, stooping, kneeling,

crouching, and crawling; and avoiding all exposure to hazards including no

hazardous heights, and operating hazardous machinery requiring use of foot

controls []. This assessment was affirmed on reconsideration []. The undersigned

has found these assessments unpersuasive. Given the claimant’s continued

complaints of peripheral neuropathy and underlying musculoskeletal concerns, as

well as nerve conduction findings in 2020 which showed severe, symmetric, length-

dependent, axonal, sensorimotor polyneuropathy [], the undersigned has found

greater functional limitation warranted as reflected in the residual functional

capacity articulated above.

(Tr. 24 (emphasis added) (internal citations omitted).) Thus, while the ALJ adopted most of the

RFC limitations recommended by the state agency medical consultants, she reduced the RFC

from light exertional work (with a limitation to four hours of standing or walking) to sedentary

exertional work (which requires no more than two hours of standing and walking) in light of Ms.

Tuttle’s “continued complaints of peripheral neuropathy,” her “underlying musculoskeletal

5 Ms. Tuttle’s briefing inaccurately characterizes the RFC as a limitation to “medium work” (ECF Doc. 9, p. 9),

when the ALJ actually limited her to the performance of “sedentary work” (Tr. 20). It is unclear whether Ms.

Tuttle’s inaccurate understanding of the RFC’s exertional level plays any role in the arguments she raises here.

concerns,” and her recent EMG findings showing “severe” polyneuropathy. Thus, the ALJ

clearly explained her reasons for adopting the exertional requirements in the final RFC.

To the extent Ms. Tuttle seeks to argue that the ALJ erred because she should have

adopted an even more restrictive RFC—one containing the need to elevate feet to waist level

multiple times throughout the day—it is not this Court’s role to “try the case de novo, nor resolve

conflicts in evidence, nor decide questions of credibility.” Garner, 745 F.2d at 387. While Ms.

Tuttle contends that her abilities are more limited than the sedentary RFC formulated by the ALJ,

she has failed to show that the ALJ lacked substantial evidence to support her RFC findings.

Accordingly, the undersigned finds Ms. Tuttle’s sole assignment of error is without merit.

VII. Recommendation

The undersigned recommends that the Court AFFIRM the Commissioner’s decision.

June 23, 2025

/s/Amanda M. Knapp

AMANDA M. KNAPP

United States Magistrate Judge

OBJECTIONS

Any objections to this Report and Recommendation must be filed with the Clerk of Courts within

fourteen (14) days after being served with a copy of this document. Failure to file objections

within the specified time may forfeit the right to appeal the District Court’s order. See Berkshire

v. Beauvais, 928 F.3d 520, 530 (6th Cir. 2019); see also Thomas v. Arn, 474 U.S. 140 (1985).

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.